- Home
- GDEV vs TARA Comparison
GDEV vs TARA Comparison
Compare GDEV & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | TARA |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 159.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GDEV | TARA |
|---|---|---|
| Price | $11.41 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 1.0K | ★ 1.3M |
| Earning Date | 11-23-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $7.58 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $2.51 |
| 52 Week High | $30.92 | $7.82 |
Technical Indicators
Market Signals| Indicator | GDEV | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 28.82 |
| Support Level | $10.92 | N/A |
| Resistance Level | $12.13 | $4.13 |
| Average True Range (ATR) | 0.54 | 0.21 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 70.05 | 16.71 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.